Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Review of preclinical studies

“This review summarizes the design rationale for GEP44 and preclinical evidence supporting its beneficial metabolic effects and tolerability.”

GEP44 reduced body weight, food intake, and fasting blood glucose in diet-induced obese rodents.

“In male DIO rats, peripheral administration of GEP44 resulted in sustained weight loss as well as reduced FI and fasting BG (FBG) (11, 49).”

GEP44 was associated with minimal gastrointestinal side effects in rodent studies.

“Importantly, GEP44 was associated with only minimal GI side effects in this rodent study (11).”